This study explores the targeted delivery of doxorubicin to breast cancer cells using aptamer-functionalized DOTAP:DOPE liposomes. Doxorubicin, a chemotherapy agent, is known for its effectiveness in treating various cancers, including breast cancer. However, its clinical application is often limited by dose-associated toxicities affecting normal cells.
The researchers adopted a novel approach by conjugating cancer cell-specific single-strand DNA aptamers with doxorubicin-encapsulated DOTAP:DOPE nanoparticles (NPs). Using a cell-SELEX strategy, they identified the aptamer SRZ1, which exhibited high specificity and binding affinity to 4T1 breast cancer cells. The study employed various cell lines, including 4T1, 67NR, and NMuMG, to examine the binding specificity and uptake efficiency of these aptamers.
The results showed that SRZ1 aptamer-carried DOTAP:DOPE-DOX NPs significantly promoted the uptake efficiency by 4T1 cells. In vitro experiments using the ATPlite assay revealed that these aptamers effectively enhanced the accumulation of doxorubicin in 4T1 tumor tissues, as confirmed by in vivo mouse body images and biodistribution analysis. Consistently, the aptamer-conjugated doxorubicin-loaded DOTAP:DOPE particles notably suppressed tumor growth and increased the survival rate of tumor-bearing mice.
This study demonstrates the potential of using aptamer-functionalized DOTAP:DOPE liposomes for targeted chemotherapy. By specifically targeting cancer cells and reducing impact on normal cells, this method presents a promising avenue for enhancing the efficacy and safety of cancer treatments.
Song, X., Ren, Y., et al. Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes. Oncology reports. 2015, 34(4): 1953-1960.
For Research Use Only. Not For Clinical Use